Li Zhang1, Jinling Wang1, Guanping Dong1, Dingwen Wu2, Wei Wu1. 1. Department of Endocrinology. 2. Department of Genetics and Metabolism, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Abstract
RATIONALE: X-linked spondyloepiphyseal dysplasia tarda (X-linked SEDT) is a rare hereditary cause in childhood short stature due to mutations in trafficking protein particle complex subunit 2 (TRAPPC2) gene located on chromosome Xp22. Several pathogenic variants in TRAPPC2 have been reported, but missense variants are rare. PATIENT CONCERNS: A 13-year, 8-month-old Chinese Han boy presenting with short stature for the past 7 years. DIAGNOSIS: X-linked SEDT was established by a combination of clinical and radiographic features, confirmed by targeted next-generation sequencing. Genetic testing of the TRAPPC2 gene revealed a novel missense variant with c.260A>C (p.H87P) hemizygote in exon5. The mother was found to be a heterozygous TRAPPC2 carrier, whereas the father was normal. INTERVENTIONS: Patient was treated with recombinant human growth hormone daily. Patient's height, glucose level, and possible progressive joint and back pain with osteoarthritis were under intensive observation regularly. OUTCOMES: The patient achieved 2.1 cm height gain over the first 3 months' recombinant human growth hormone treatment without joint or back pain. However, the therapy was terminated because of increased glucose level on follow-up. LESSONS: The short stature is a noteworthy problem for X-linked SEDT cases. We report a novel missense variant site in TRAPPC2 treated with growth hormone in the literature. We do not recommend the use of recombinant human growth hormone on patients with X-linked SEDT for the concern of glucose homeostasis.
RATIONALE: X-linked spondyloepiphyseal dysplasia tarda (X-linked SEDT) is a rare hereditary cause in childhood short stature due to mutations in trafficking protein particle complex subunit 2 (TRAPPC2) gene located on chromosome Xp22. Several pathogenic variants in TRAPPC2 have been reported, but missense variants are rare. PATIENT CONCERNS: A 13-year, 8-month-old Chinese Han boy presenting with short stature for the past 7 years. DIAGNOSIS: X-linked SEDT was established by a combination of clinical and radiographic features, confirmed by targeted next-generation sequencing. Genetic testing of the TRAPPC2 gene revealed a novel missense variant with c.260A>C (p.H87P) hemizygote in exon5. The mother was found to be a heterozygous TRAPPC2 carrier, whereas the father was normal. INTERVENTIONS: Patient was treated with recombinant human growth hormone daily. Patient's height, glucose level, and possible progressive joint and back pain with osteoarthritis were under intensive observation regularly. OUTCOMES: The patient achieved 2.1 cm height gain over the first 3 months' recombinant human growth hormone treatment without joint or back pain. However, the therapy was terminated because of increased glucose level on follow-up. LESSONS: The short stature is a noteworthy problem for X-linked SEDT cases. We report a novel missense variant site in TRAPPC2 treated with growth hormone in the literature. We do not recommend the use of recombinant human growth hormone on patients with X-linked SEDT for the concern of glucose homeostasis.
Authors: Christopher J Westlake; Lisa M Baye; Maxence V Nachury; Kevin J Wright; Karen E Ervin; Lilian Phu; Cecile Chalouni; John S Beck; Donald S Kirkpatrick; Diane C Slusarski; Val C Sheffield; Richard H Scheller; Peter K Jackson Journal: Proc Natl Acad Sci U S A Date: 2011-01-27 Impact factor: 11.205
Authors: Mei Y Choi; Caleb C Y Chan; Danny Chan; Keith D K Luk; Kathryn S E Cheah; Julian A Tanner Journal: Biochem J Date: 2009-09-25 Impact factor: 3.857
Authors: Y Ohata; S Takeyari; Y Nakano; T Kitaoka; H Nakayama; V Bizaoui; K Yamamoto; K Miyata; K Yamamoto; M Fujiwara; T Kubota; T Michigami; K Yamamoto; T Yamamoto; N Namba; K Ebina; H Yoshikawa; K Ozono Journal: Osteoporos Int Date: 2019-07-29 Impact factor: 4.507
Authors: Jeshmi Jeyabalan; M Andrew Nesbit; Juris Galvanovskis; Richard Callaghan; Patrik Rorsman; Rajesh V Thakker Journal: PLoS One Date: 2010-05-14 Impact factor: 3.240